Braden Michael Leonard sold $2.9M of ANTX
owner at AN2 Therapeutics, Inc.. 2,532,000 shares at an average of $1.13, traded May 28, 2025, filed May 30, 2025.
Score components
- +12Role10% owner
- +25Trade size$2.9M at market
- +10Share of holdings soldSold 44% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001373604-25-000084, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 28, 2025 | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -2,000,000 | $1.16 | $2.3M | 3,749,432 | May 30, 2025 |
| May 28, 2025 | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -100,000 | $1.16 | $116k | 3,649,432 | May 30, 2025 |
| May 30, 2025 | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -425,000 | $1.01 | $429k | 3,224,432 | May 30, 2025 |
| May 30, 2025 | SOpen-market sale Common Stockindirect: Holding of BML Investment Partners, L.P. | -7,000 | $1.03 | $7,227 | 3,217,432 | May 30, 2025 |
Related signals
Other insiders at AN2 Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $6,675 1,108 shares | -0% | |
| 13Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $97k 16,119 shares | -3% | |
| 23Weak | AN2 Therapeutics, Inc. | Sarah Joanne Williams Principal Accounting Officer | $1,504 272 shares | -0% | |
| 21Weak | ANTXbuy AN2 Therapeutics, Inc. | Margaret M FitzPatrick director | $12k 2,098 shares | +24% | |
| 15Weak | ANTXsell AN2 Therapeutics, Inc. | Sarah Joanne Williams Principal Accounting Officer | $347 327 shares | -0% | |
| 35Weak | AN2 Therapeutics, Inc. | Joshua M Eizen See Remarks | $25k 24,854 shares | -14% | |
| 35Weak | AN2 Therapeutics, Inc. | Sanjay Chanda Chief Development Officer | $9,332 9,251 shares | -11% | |
| 30Weak | AN2 Therapeutics, Inc. | Stephen David Prior Chief Strategy Officer | $6,507 6,462 shares | -10% | |
| 42Moderate | AN2 Therapeutics, Inc. | Lucy Day Chief Financial Officer | $8,883 8,807 shares | -10% | |
| 23Weak | AN2 Therapeutics, Inc. | Stephen David Prior Chief Strategy Officer | $872 765 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.